William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.
Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.
Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.
Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.
Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.
Daniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.
Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.
Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.
J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.
Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.
Ajay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.
Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.
Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.
Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Sophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.
Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.
Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.
Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
A University of Arizona project, with funding from the state's New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.
Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.
Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.
Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.
Matthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.